Boustead Singapore ( (SG:F9D) ) just unveiled an update.
Boustead Singapore’s Real Estate Solutions Division has secured a significant design-and-build contract for a pharmaceutical facility in Tuas Biomedical Park, aimed at enhancing the client’s global network and meeting growing demand for drug discoveries. This contract, along with a previous data center project, increases the division’s order backlog to S$249 million, although it is not expected to materially impact the group’s profitability in the short term.
More about Boustead Singapore
Boustead Singapore Limited is a global infrastructure-related engineering and technology group, primarily involved in the engineering and construction sector through its Real Estate Solutions Division, Boustead Projects Limited. The company focuses on providing design-and-build solutions, particularly in the pharmaceutical sector, leveraging its expertise to deliver specialized facilities that meet high specification manufacturing needs.
Technical Sentiment Signal: Buy
Current Market Cap: $388.4M
Learn more about F9D stock on TipRanks’ Stock Analysis page.